ERCC1、BRCA1在非小细胞肺癌的表达与顺铂耐药的研(3)
2014-03-04 01:05
导读：[5] Matakidou A, el Galta R, Webb EL, et al. Genetic variation in the DNA repair genes is predictive of outcome in lung cancer[J]. Hum Mol Genet, 2007,16:2333-2340. [6] Croteau DL, Peng Y, Van Houten
[5] Matakidou A, el Galta R, Webb EL, et al. Genetic variation in the DNA repair genes is predictive of outcome in lung cancer[J]. Hum Mol Genet, 2007,16:2333-2340.
[6] Croteau DL, Peng Y, Van Houten B. DNA repair gets physical: Mapping an XPA-binding site on ERCC1[J]. DNA Repair,2008,5: 819-826
[7] Tsodikov OV, Ivanov D, Orelli B, et al. Structural basis for the recruitment of ERCC1-XPF to nucleotide excision repair complexes by XPA[J]. EMBO,2007,26:4768-4776.
[8] Gossage L, Madhusudan S. Current status of excision repair cross complementing-group 1 (ERCC1) in cancer[J]. Cancer Treat Rev, 2007,33:565-577.
[9] Park SY, Hong YC, Kim JH, et al. Effect of ERCC1 polymorphisms and the modification by smoking on the survival of non-small cell lung cancer patients[J]. Med Oncol,2006,23:489-498.
[10] Ryu JS, Viguier J, Praz F. Genetic effect of ERCC1 codon 118 polymorphism and confounding factors[J]. Clin Cancer Res, 2006,12: 4784-4785.
[11] Rosell R, Taron M, Barnadas A, et al. Nucleotide excision repair pathways involved in Cisplatin resistance in non-small-cell lung cancer[J]. Cancer Control,2003,10:297-305.
[12] Monzo M, Rosell R, Taron M. Drug resistance in non-small cell lung cancer[J]. Lung Cancer,2001,34 (Suppl 2):S91-S94.
[13] Cobo M, Isla D, Massuti B, et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer[J]. Clin Oncol, 2007,25:2747-2754.
[14] Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy[J]. N Engl J Med,2006,355:983-991.
[15] Wiwanitkit V. Molecular structure of BRCA1-estrogen receptor alpha-estrogen complex: relevance to breast cancer?[J]. Asian Pac Cancer Prev,2005,6:561-562.
[16] Tassone P, Tagliaferri P, Perricelli A, et al. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells[J]. Br Cancer,2003,88:1285-1291.
（转载自http://zw.NSEAC.com科教作文网）
[17] Muraoka-Cook RS, Caskey LS, Sandahl MA, et al. Heregulin-dependent delay in mitotic progression requires HER4 and BRCA1[J]. Mol Cell Biol, 2006,26:6412-6424.
[18] Kennedy RD, Quinn JE, Mullan PB, et al. The role of BRCA1 in the cellular response to chemotherapy[J]. Natl Cancer Inst, 2004,96:1659-1668.
[19] Sgagias MK, Wagner KU, Hamik B, et al. Brca1-deficient murine mammary epithelial cells have increased sensitivity to CDDP and MMS[J]. Cell Cycle, 2004,3:1451-1456.
